Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Oldest-in-Human Successful Extraction Experience of a Novel Substernal Extravascular Defibrillator.
J Cardiovasc Electrophysiol
January 2025
University of Melbourne, Melbourne, Parkville, Victoria, Australia.
Introduction: Substernal extravascular defibrillators (EV ICDs) have been shown to be effective and safe for patients at risk of sudden cardiac death, however, there is little evidence around the safety of extracting chronic devices.
Methods And Results: We present a 50-year-old patient in whom a Medtronic EV ICD system was successfully removed without specialist extraction tools, 186 weeks after implantation, by an operator experienced in transvenous lead extraction but without formal training in EVICD implantation.
Conclusion: The successful extraction of an EV ICD system is possible without specialised tools at least 3.
Aims: The extravascular implantable cardioverter-defibrillator (EV ICD) has been shown to be safe and effective for patients at risk of sudden cardiac death, but little is known about EV ICD lead removal in humans. This analysis aimed to characterize the EV ICD lead removal experience thus far.
Methods And Results: This was a retrospective analysis of lead removals from the EV ICD Pilot, Pivotal, and Continued Access Studies.
External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Cochrane Database Syst Rev
June 2024
Barts Heart Centre, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
Article Synopsis
- Atrial fibrillation (AF) is a common heart rhythm disorder, and cardioversion is a method used to return the heart to its normal rhythm through medications or electrical shocks.
- The study aimed to evaluate the effectiveness and safety of both pharmacological and electrical cardioversion treatments for AF and related conditions.
- Researchers analyzed data from 112 randomized controlled trials involving nearly 16,000 patients, noting that many trials had a high risk of bias and varying demographics among participants.
Comparison of outcomes and required tools between transvenous extraction of pacemaker and implantable cardioverter defibrillator leads: Insight from single high-volume center experience.
J Cardiovasc Electrophysiol
July 2024
Department of Cardiovascular Medicine, Cardiac Electrophysiology and Pacing Section, Cleveland Clinic, Cleveland, Ohio, USA.
Introduction: Reports of comparison with procedural outcomes for implantable cardioverter defibrillator (ICD) and pacemaker (PM) transvenous lead extraction (TLE) are old and limited. We sought to compare the safety, efficacy, and procedural properties of ICD and PM TLE and assess the impact of lead age.
Methods: The study cohort included all consecutive patients with ICD and PM TLE in the Cleveland Clinic Prospective TLE Registry between 2013 and 2022.
Sex differences among subcutaneous implantable cardioverter-defibrillator recipients: a propensity-matched, multicentre, international analysis from the i-SUSI project.
Europace
May 2024
Cardiology Unit, Luigi Sacco University Hospital, Milan, Italy.
Article Synopsis
- The study investigates sex differences in outcomes among recipients of subcutaneous implantable cardioverter-defibrillators (S-ICDs), noting that historically, women have been underrepresented in such trials.
- Using a multicenter international registry, researchers compared 399 females to a matched cohort of males, focusing on the rate of appropriate shocks and device complications over time.
- Results showed that women had a lower rate of appropriate shocks compared to men (1.7% vs. 3.4% per year), but no significant difference in device-related complications, indicating that while women are less likely to receive effective ICD therapy, they face no increased risk of adverse effects from the devices.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!